TW200938633A - Vaccine - Google Patents

Vaccine Download PDF

Info

Publication number
TW200938633A
TW200938633A TW097147198A TW97147198A TW200938633A TW 200938633 A TW200938633 A TW 200938633A TW 097147198 A TW097147198 A TW 097147198A TW 97147198 A TW97147198 A TW 97147198A TW 200938633 A TW200938633 A TW 200938633A
Authority
TW
Taiwan
Prior art keywords
asn
protein
seq
asp
ala
Prior art date
Application number
TW097147198A
Other languages
English (en)
Chinese (zh)
Inventor
Joseph D Cohen
Martine Marchand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200938633(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of TW200938633A publication Critical patent/TW200938633A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
TW097147198A 2007-12-06 2008-12-04 Vaccine TW200938633A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99280207P 2007-12-06 2007-12-06

Publications (1)

Publication Number Publication Date
TW200938633A true TW200938633A (en) 2009-09-16

Family

ID=40591828

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097147198A TW200938633A (en) 2007-12-06 2008-12-04 Vaccine

Country Status (20)

Country Link
EP (1) EP2227550A2 (es)
JP (1) JP2011505796A (es)
KR (1) KR20100108544A (es)
CN (1) CN101939438A (es)
AR (1) AR069568A1 (es)
AU (1) AU2008333208A1 (es)
BR (1) BRPI0819889A2 (es)
CA (1) CA2707245A1 (es)
CL (1) CL2008003614A1 (es)
CO (1) CO6300795A2 (es)
CR (1) CR11537A (es)
DO (1) DOP2010000164A (es)
IL (1) IL205953A0 (es)
MA (1) MA32003B1 (es)
MX (1) MX2010006207A (es)
PE (1) PE20091106A1 (es)
TW (1) TW200938633A (es)
UY (1) UY31510A1 (es)
WO (1) WO2009071613A2 (es)
ZA (1) ZA201003851B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
EP2694099B1 (en) * 2011-04-08 2019-10-16 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110687289B (zh) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Fgl2蛋白作为疟疾感染标志物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
PL376792A1 (pl) * 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
EP1573012B1 (en) * 2002-12-17 2011-11-30 Crucell Holland B.V. Recombinant viral-based malaria vaccines
WO2005063805A1 (en) * 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
CA2553541C (en) * 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Chimpanzee adenovirus vaccine carriers
PT1802336E (pt) * 2004-10-14 2011-11-15 Glaxosmithkline Biolog Sa Vacinas de dose inicial/reforço para a malária
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1998804B1 (en) * 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
AU2007276219B2 (en) * 2006-07-18 2013-10-03 Glaxosmithkline Biologicals S.A. Vaccines for malaria
EP2137210B1 (en) * 2007-03-02 2016-10-19 GlaxoSmithKline Biologicals SA Novel method and compositions
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors

Also Published As

Publication number Publication date
CL2008003614A1 (es) 2010-01-15
AU2008333208A1 (en) 2009-06-11
DOP2010000164A (es) 2010-07-31
MA32003B1 (fr) 2011-01-03
WO2009071613A2 (en) 2009-06-11
MX2010006207A (es) 2010-10-04
UY31510A1 (es) 2009-08-03
EP2227550A2 (en) 2010-09-15
ZA201003851B (en) 2012-11-28
BRPI0819889A2 (pt) 2015-06-16
CN101939438A (zh) 2011-01-05
WO2009071613A3 (en) 2009-08-13
CA2707245A1 (en) 2009-06-11
IL205953A0 (en) 2010-11-30
PE20091106A1 (es) 2009-08-24
JP2011505796A (ja) 2011-03-03
KR20100108544A (ko) 2010-10-07
CO6300795A2 (es) 2011-07-21
AR069568A1 (es) 2010-02-03
CR11537A (es) 2010-08-18

Similar Documents

Publication Publication Date Title
EP2998316B1 (en) Novel method and compositions
AU2007276219B2 (en) Vaccines for malaria
ES2388527T3 (es) Vacunas de VIH basadas en Env de múltiples clados de VIH
US20100272786A1 (en) Vaccine
US20110236468A1 (en) Vaccine compositions
RU2585228C2 (ru) Модификация рекомбинантного аденовируса иммуногенными эпитопами белка circumsporozoite плазмодия
US11857611B2 (en) Compositions and methods for generating an immune response to treat or prevent malaria
KR20210013589A (ko) 면역 체크포인트 억제제 공동-발현 벡터
KR20200066349A (ko) 복제 가능 아데노바이러스 벡터
TW200938633A (en) Vaccine
WO2012023995A1 (en) Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
KR20200027551A (ko) Cea muc1 및 tert를 포함하는 면역원성 조성물
KR20230051529A (ko) 리소좀 장애에 대한 유전자 요법
WO2020201191A1 (en) Multivalent malaria transmission-blocking vaccines
CN101522212A (zh) 用于疟疾的疫苗